Analyzing proteins and maternal factors in neonatal septic shock
Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates Born to ≤32-week Preterm Infants or Infected Mothers During Pregnancy
This study is trying to see how infections in pregnant mothers might affect premature babies and their risk of developing septic shock after birth.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 116 (estimated) |
| Ages | 1 Day to 1 Day |
| Sex | All |
| Sponsor | Guangdong Women and Children Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06206590 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on premature infants born at or before 32 weeks of gestation and examines the influence of maternal infections during pregnancy on the occurrence of septic shock in newborns. By collecting maternal blood samples before delivery and umbilical cord blood samples at birth, researchers will conduct whole proteomic analyses to identify differential proteins associated with septic shock. The study aims to understand the relationship between these proteins and the prognosis of affected infants, ultimately seeking to provide early warning signs to prevent and reduce the incidence of septic shock in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are premature infants born at or before 32 weeks of gestation or newborns delivered by mothers who had infections during pregnancy.
Not a fit: Patients who are not delivered in the participating hospital or have congenital malformations or genetic metabolic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention strategies for septic shock in premature infants.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding the role of maternal factors in neonatal outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All ≤32-week premature infants admitted to our NICU; All newborns delivered by the mother infected during pregnancy Exclusion Criteria: * Not delivered in our hospital; congenital cardiovascular development malformation, fetal malformation, genetic metabolic diseases, etc
Where this trial is running
Guangzhou, Guangdong
- Guangdong Women and Children Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: dongju ma
- Email: 864970051@qq.com
- Phone: +86 188 9853 7230
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.